Loading…
CIK 0001910264 • 6 13F filings • May 13, 2025 – Aug 12, 2026
Import this data to Google Sheets with:
=jivedata("sr-one-capital-management-lp","13f")Uses this filer's slug. Install the Jive Data add-on first; the second argument is "13f".
Past 5 quarters
| % of Portfolio | |||||
|---|---|---|---|---|---|
| Alumis Inc. | Common Stock | $19.1M | 2.7%Prev: 1.1% | 1,959,896 SH | Increased |
| Arcellx, Inc. | Common Stock | $153.0M | 21.7%Prev: 27.9% | 2,346,630 SH | Decreased |
| ARS Pharmaceuticals, Inc. | Common Stock | $46.8M | 6.6%Prev: 5.8% | 4,012,903 SH | Increased |
| CRISPR Therapeutics AG | Common Shares | $106.9M | 15.1%Prev: 19.1% | 2,038,763 SH | Decreased |
| Design Therapeutics, Inc. | Common Stock | $61.2M | 8.7%Prev: 7.1% | 6,526,476 SH | Increased |
| enGene Holdings Inc. | Common Shares | $6.8M | 1.0%Prev: 0.7% | 747,750 SH | Increased |
| Mineralys Therapeutics Inc. | Common Stock | $56.8M | 8.0%Prev: 11.6% | 1,563,966 SH | Decreased-549,967 SH |
| Nkarta, Inc. | Common Stock | $6.2M | 0.9%Prev: 1.0% | 3,333,333 SH | Decreased |
| Oculis Holding AG | Ordinary Shares | $12.8M | 1.8%Prev: 0.8% | 641,022 SH | Increased+318,522 SH |
| ORIC Pharmaceuticals, Inc. | Common Stock | $37.8M | 5.3%Prev: 7.8% | 4,514,929 SH | Decreased |
| Oruka Therapeutics, Inc | Common Stock | $13.0M | 1.8%Prev: 1.2% | 430,330 SH | Increased |
| Ultragenyx Pharmaceutical Inc. | Common Stock | $3.2M | 0.4% | 137,753 SH | New |
| Zenas BioPharma, Inc | Common Stock | $182.9M | 25.9%Prev: 15.8% | 5,037,854 SH | Increased+126,315 SH |
| 13F-HR |
| 0001193125-26-347065 |
| $1.04B |
| View |
| Aug 14, 2025 | Q2 2025 | 13F-HR | 0000950123-25-008422 | $461.4M | View |
| May 14, 2026 | Q1 2026 | 13F-HR | 0001193125-26-224136 | $915.4M | View |
| May 13, 2025 | Q1 2025 | 13F-HR | 0000950123-25-004926 | $389.3M | View |